BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Argus Health
Healthtrust
Teva
Fish and Richardson
Merck
Chinese Patent Office
Cipla
Baxter
UBS

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,947,295

« Back to Dashboard

Which drugs does patent 7,947,295 protect, and when does it expire?

Patent 7,947,295 protects ILEVRO and is included in one NDA.

This patent has thirty-six patent family members in fifteen countries.
Summary for Patent: 7,947,295
Title:Ophthalmic compositions containing a synergistic combination of two polymers
Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
Inventor(s): Chowhan; Masood A. (Arlington, TX), Chen; Huagang (Arlington, TX)
Assignee: Alcon, Inc. (Hunenberg, CH)
Application Number:11/673,070
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 7,947,295

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,947,295

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,709,012 Ophthalmic compositions containing a synergistic combination of two polymers ➤ Subscribe
8,313,754 Ophthalmic compositions containing a synergistic combination of two polymers ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,947,295

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004249137 ➤ Subscribe
Australia 2010200297 ➤ Subscribe
Australia 2012205283 ➤ Subscribe
Brazil PI0411361 ➤ Subscribe
Canada 2527712 ➤ Subscribe
Canada 2839847 ➤ Subscribe
Canada 2839849 ➤ Subscribe
Canada 2839898 ➤ Subscribe
Canada 2839928 ➤ Subscribe
Canada 2839930 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Julphar
Johnson and Johnson
Farmers Insurance
Deloitte
Daiichi Sankyo
Moodys
Accenture
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot